[Keloid scars (part I): Clinical presentation, epidemiology, histology and pathogenesis]

C Philandrianos; N Kerfant; C Jaloux Jr; L Martinet; B Bertrand; D Casanova

doi:10.1016/j.anplas.2015.09.005

[Keloid scars (part I): Clinical presentation, epidemiology, histology and pathogenesis]

Ann Chir Plast Esthet. 2016 Apr;61(2):128-35. doi: 10.1016/j.anplas.2015.09.005. Epub 2015 Nov 3.

[Article in French]

Authors

C Philandrianos¹, N Kerfant², C Jaloux Jr³, L Martinet⁴, B Bertrand³, D Casanova³

Affiliations

¹ Service de chirurgie plastique et réparatrice, hôpital Nord, AP-HM, CHU de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France. Electronic address: [email protected].
² Service de chirurgie plastique, CHRU La Cavale Blanche, boulevard Tanguy-Prigent, 29609 Brest, France.
³ Service de chirurgie plastique et réparatrice, hôpital Nord, AP-HM, CHU de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France.
⁴ Clinique Jules-Vernes, 2, route de Paris, 44300 Nantes, France.

PMID: 26545809
DOI: 10.1016/j.anplas.2015.09.005

Abstract

Keloid scars are a dysregulated response to cutaneous wound healing and are characterized by excessive deposition of collagen. Clinical and histological aspects are typical but they are often confused with hypertrophic scars. Principal pathogenesis is abnormal regulation of the collagen equilibrium because of TGFβ. In this first part, clinical characteristics, physiopathology and histology of keloid scars are explained.

Keywords: Chéloïde; Cicatrice; Collagen bundle; Collagène hyalin; Fibroblast; Fibroblaste; Fibrose; Fibrosis; Keloid; Scar; TGFβ.

Publication types

Review

MeSH terms

Apoptosis
Collagen / metabolism
Fibroblasts / pathology
Humans
Keloid / epidemiology
Keloid / metabolism
Keloid / pathology*
Risk Factors
Transforming Growth Factor beta / metabolism

Substances

Transforming Growth Factor beta
Collagen